PEN
Penumbra IncPrice & Indicators
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from its earnings releases, calls, and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Global embolization and access revenue | $120.8M | first quarter of 2026 | — |
| Global thrombectomy revenue | $253.9M | first quarter of 2026 | — |
| Gross profit margin | 67.6% | first quarter of 2026 | — |
| adjusted EBITDA non-GAAP | $266.8M | Full Year 2025 | — |
| adjusted EBITDA margin non-GAAP | 20.5% | Q4 2025 | — |
Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
PEN
this stock
Penumbra Inc
|
$12.52B | +2.4% | +17.5% | 73.3 | 5.1% |
|
ABT
Abbott Laboratories
|
$165.79B | -23.6% | +5.7% | 26.7 | 1.3% |
|
SYK
Stryker Corp
|
$126.41B | -5.9% | +11.2% | 38.2 | 1.6% |
|
MDT
Medtronic plc
|
$107.31B | -12.0% | +8.4% | 22.5 | 1.4% |
|
BSX
Boston Scientific Corp
|
$67.33B | -52.5% | +5.5% | 19.0 | 2.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| PEN | +0.9% | -0.7% | -0.4% | +0.8% | +2.4% |
| SPY | +0.9% | +1.4% | +7.6% | +0.1% | +9.7% |
| vs SPY | 0.0% | -2.1% | -7.9% | +0.7% | -7.3% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.